Pharmacological & Non-Pharmacological Management of COPD Flashcards

Which class of medications is considered first-line maintenance therapy for COPD?

Answer: Long-acting muscarinic antagonists (LAMAs) or long-acting beta-agonists (LABAs)

Long-acting bronchodilators, specifically Long-Acting Muscarinic Antagonists (LAMAs) and Long-Acting Beta-Agonists (LABAs), are the cornerstone of maintenance therapy for COPD. They work by relaxing the smooth muscles around the airways, keeping them open for extended periods, which reduces symptoms, improves lung function, and enhances quality of life.

What is the primary benefit of combining LAMA and LABA therapies in COPD?

Answer: Provides greater bronchodilation and symptom improvement

Combining a LAMA and a LABA utilizes two different bronchodilator mechanisms, leading to synergistic effects on airway smooth muscle relaxation. This dual bronchodilation results in more significant improvements in lung function, reduced dyspnea, and better quality of life compared to monotherapy, making it a preferred strategy for many COPD patients.

When should inhaled corticosteroids (ICS) be added to COPD treatment?

Answer: In patients with frequent exacerbations despite LAMA/LABA therapy

Inhaled corticosteroids (ICS) are generally not recommended as monotherapy for COPD due to potential side effects and limited efficacy in all patients. They are primarily indicated as an add-on therapy for patients who experience frequent exacerbations (e.g., two or more moderate exacerbations or one hospitalization per year) despite optimal bronchodilator therapy with LAMA/LABA.

What is the most effective non-pharmacological intervention for stable COPD patients?

Answer: Pulmonary rehabilitation

Pulmonary rehabilitation is a comprehensive, multidisciplinary program that includes exercise training, education, and psychosocial support. It is highly effective in improving exercise capacity, reducing dyspnea, enhancing quality of life, and decreasing hospitalizations in stable COPD patients, making it a cornerstone of non-pharmacological management.

Which vaccination is strongly recommended for all COPD patients?

Answer: Influenza and pneumococcal vaccines

COPD patients are highly susceptible to respiratory infections, which can trigger severe exacerbations, leading to hospitalization and increased mortality. Influenza and pneumococcal vaccines are strongly recommended to reduce the risk and severity of these infections, thereby improving patient outcomes and preventing disease progression.

What is the primary indication for long-term oxygen therapy (LTOT) in COPD?

Answer: Severe resting hypoxemia (PaO2 ≤ 55 mmHg or SpO2 ≤ 88%)

Long-term oxygen therapy (LTOT) is prescribed for COPD patients with severe chronic resting hypoxemia to improve survival and reduce the risk of complications like pulmonary hypertension. It is indicated when arterial oxygen levels fall below specific thresholds, typically PaO2 ≤ 55 mmHg or SpO2 ≤ 88% at rest, or slightly higher with signs of cor pulmonale.

Which breathing technique is taught to COPD patients to reduce dyspnea?

Answer: Pursed-lip breathing

Pursed-lip breathing is a simple yet effective technique taught to COPD patients to manage dyspnea. It helps to slow down exhalation, create back-pressure in the airways, and prevent premature airway collapse, thereby reducing air trapping and improving gas exchange, making breathing feel less labored.

What is the role of mucolytics like N-acetylcysteine in COPD management?

Answer: Reduce exacerbations in patients with chronic bronchitis

Mucolytics like N-acetylcysteine work by thinning mucus, making it easier to clear from the airways. In COPD patients, particularly those with chronic bronchitis who experience excessive mucus production, this can significantly reduce the frequency and severity of exacerbations by improving airway clearance and reducing bacterial colonization.

Which surgical option may be considered for select patients with severe emphysema?

Answer: Lung volume reduction surgery (LVRS)

Lung volume reduction surgery (LVRS) is a surgical option for carefully selected patients with severe emphysema, typically those with upper lobe predominant disease and low exercise capacity. This procedure removes damaged, non-functional lung tissue, allowing healthier lung tissue to expand more efficiently, improving breathing mechanics and exercise tolerance.